TY - JOUR
T1 - Metastatic pancreatic cancer
T2 - ASCO guideline update
AU - Sohal, Davendra P.S.
AU - Kennedy, Erin B.
AU - Cinar, Pelin
AU - Conroy, Thierry
AU - Copur, Mehmet S.
AU - Crane, Christopher H.
AU - Garrido-Laguna, Ignacio
AU - Lau, Michelle W.
AU - Johnson, Tyler
AU - Krishnamurthi, Smitha
AU - Moravek, Cassadie
AU - O'Reilly, Eileen M.
AU - Philip, Philip A.
AU - Pant, Shubham
AU - Shah, Manish A.
AU - Sahai, Vaibhav
AU - Uronis, Hope E.
AU - Zaidi, Neeha
AU - Laheru, Daniel
N1 - Publisher Copyright:
Copyright © 2020 American Society of Clinical Oncology. All rights reserved.
PY - 2020/9/20
Y1 - 2020/9/20
N2 - PURPOSE The aim of this work was to provide an update to the ASCO guideline on metastatic pancreatic cancer pertaining to recommendations for therapy options after first-line treatment. METHODS ASCO convened an Expert Panel and conducted a systematic review to update guideline recommendations for second-line therapy for metastatic pancreatic cancer. RESULTS One randomized controlled trial of olaparib versus placebo, one report on phase I and II studies of larotrectinib, and one report on phase I and II studies of entrectinib met the inclusion criteria and inform the guideline update. RECOMMENDATIONS New or updated recommendations for germline and somatic testing for microsatellite instability high/mismatch repair deficiency, BRCA mutations, and TRK alterations are provided for all treatmenteligible patients to select patients for recommended therapies, including pembrolizumab, olaparib, larotrectinib, or entrectinib, or potential clinical trials. The Expert Panel continues to endorse the remaining recommendations for second-line chemotherapy, as well as other recommendations related to treatment, follow-up, and palliative care from the 2018 version of this guideline. Additional information is available at www.asco.org/gastrointestinalcancer- guidelines.
AB - PURPOSE The aim of this work was to provide an update to the ASCO guideline on metastatic pancreatic cancer pertaining to recommendations for therapy options after first-line treatment. METHODS ASCO convened an Expert Panel and conducted a systematic review to update guideline recommendations for second-line therapy for metastatic pancreatic cancer. RESULTS One randomized controlled trial of olaparib versus placebo, one report on phase I and II studies of larotrectinib, and one report on phase I and II studies of entrectinib met the inclusion criteria and inform the guideline update. RECOMMENDATIONS New or updated recommendations for germline and somatic testing for microsatellite instability high/mismatch repair deficiency, BRCA mutations, and TRK alterations are provided for all treatmenteligible patients to select patients for recommended therapies, including pembrolizumab, olaparib, larotrectinib, or entrectinib, or potential clinical trials. The Expert Panel continues to endorse the remaining recommendations for second-line chemotherapy, as well as other recommendations related to treatment, follow-up, and palliative care from the 2018 version of this guideline. Additional information is available at www.asco.org/gastrointestinalcancer- guidelines.
UR - http://www.scopus.com/inward/record.url?scp=85092477609&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092477609&partnerID=8YFLogxK
U2 - 10.1200/JCO.20.01364
DO - 10.1200/JCO.20.01364
M3 - Review article
C2 - 32755482
AN - SCOPUS:85092477609
SN - 0732-183X
VL - 38
SP - 3217
EP - 3230
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 27
ER -